Evaluating imaging methods for diagnosing Giant Cell Arteritis
Post-therapeutic Imaging Evaluation of Patients With Horton's Disease (Giant Cell Arteritis)
Fondation Ophtalmologique Adolphe de Rothschild · NCT06004154
This study is testing whether non-invasive imaging methods like MRI and ultrasound can help diagnose Giant Cell Arteritis better than the usual biopsy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Fondation Ophtalmologique Adolphe de Rothschild (network) |
| Locations | 1 site (Paris) |
| Trial ID | NCT06004154 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients diagnosed with Giant Cell Arteritis (GCA), also known as Horton's disease, which can lead to serious complications if not diagnosed and treated promptly. The study aims to assess the effectiveness of non-invasive imaging techniques, such as MRI and ultrasound, as alternatives to the traditional temporal artery biopsy for diagnosing GCA. By utilizing these imaging methods, the study seeks to improve diagnostic accuracy and reduce the need for invasive procedures. Participants will be monitored to evaluate the outcomes of these imaging evaluations in the context of their GCA diagnosis.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 50 and over who have been diagnosed with Giant Cell Arteritis according to the latest ACR/EULAR criteria.
Not a fit: Patients with contraindications to MRI or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate and less invasive diagnostic methods for patients with Giant Cell Arteritis.
How similar studies have performed: Other studies have shown promise in using imaging techniques for diagnosing similar conditions, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient aged 50 and over * Having received informed consent to participate in the study * Affiliated or beneficiary of a social insurance scheme * Patients with giant cell arteritis according to ACR/EULAR 2022 criteria * Diagnosed with MRI and ultrasound. Exclusion Criteria: * Absolute or relative contraindication to MRI (incompatible implantable device, claustrophobia, etc.) * Hypersensitivity to gadobutrol * Patient under legal protection * Pregnant or breast-feeding women
Where this trial is running
Paris
- Hopital Fondation Adolphe de Rothschild — Paris, France (RECRUITING)
Study contacts
- Study coordinator: Amélie Yavchitz, PhD
- Email: ayavchitz@for.paris
- Phone: 0148036454
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Giant Cell Arteritis